Holen Sie sich die Stockscreener-App
52.70
1.35%
0.295
Schlusskurs vom Vortag:
$52.41
Offen:
$52.33
24-Stunden-Volumen:
1.73M
Relative Volume:
0.57
Marktkapitalisierung:
$10.06B
Einnahmen:
$2.83B
Nettoeinkommen (Verlust:
$-1.02B
KGV:
-9.5653
EPS:
-5.51
Netto-Cashflow:
$194.14M
1W Leistung:
+1.41%
1M Leistung:
+11.90%
6M Leistung:
+12.81%
1J Leistung:
-22.71%
1-Tages-Spanne:
$51.75
$53.29
1-Wochen-Bereich:
$51.75
$53.96
52-Wochen-Spanne:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
53.12 | 9.92B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
468.00 | 177.38B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
185.91 | 135.85B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
627.17 | 51.87B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
124.38 | 35.70B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
181.24 | 31.70B | 15.70B | 1.24B | 2.01B | 6.91 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups - ADVFN
Exact Sciences (EXAS): Exploring Current Valuation After Recent Share Price Swings - Yahoo Finance
Pallas Capital Advisors LLC Boosts Holdings in Exact Sciences Corporation $EXAS - MarketBeat
273,936 Shares in Exact Sciences Corporation $EXAS Purchased by Kingstone Capital Partners Texas LLC - MarketBeat
Matthew Lillard Knows There's Nothing Scary About Screening for Colon Cancer: (Exclusive) - People.com
Exact Sciences : Latest Corporate Presentation - MarketScreener
Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test - Yahoo Finance
Exact Sciences, Healthmine Partner to Boost Cologuard Screening Rates via Health Plan Incentives - Insider Monkey
Exact Sciences Corporation (NASDAQ:EXAS) Short Interest Update - MarketBeat
Zevenbergen Capital Investments LLC Sells 149,781 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Brokerages Set Exact Sciences Corporation (NASDAQ:EXAS) Target Price at $68.05 - MarketBeat
Can Exact Sciences Corporation generate free cash flow2025 Analyst Calls & Fast Gaining Stock Strategy Reports - خودرو بانک
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 1,707,287 Shares of Exact Sciences Corporation $EXAS - MarketBeat
EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive Care - Yahoo Finance
Q3 EPS Estimates for Exact Sciences Boosted by William Blair - MarketBeat
DLD Asset Management LP Invests $3.40 Million in Exact Sciences Corporation $EXAS - MarketBeat
Nasdaq Moves: Should I set a stop loss on QRHCJuly 2025 PostEarnings & Low Risk High Reward Ideas - خودرو بانک
Woodline Partners LP Increases Stock Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Aug Sectors: Is Exact Sciences Corporation showing insider buyingChart Signals & Weekly Chart Analysis and Trade Guides - خودرو بانک
Belpointe Asset Management LLC Has $2.26 Million Stake in Exact Sciences Corporation $EXAS - MarketBeat
FY2025 EPS Estimates for Exact Sciences Lifted by Analyst - MarketBeat
Exact Sciences CEO on Launch of Multi-Cancer Blood Test - MarketScreener
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Energy Moves: Is CARGO Therapeutics Inc. forming bullish engulfing patternsIPO Watch & Weekly Sector Rotation Insights - خودرو بانک
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Sahm
Scientech Research LLC Makes New $915,000 Investment in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences (NASDAQ:EXAS) Given New $85.00 Price Target at Craig Hallum - MarketBeat
Curi RMB Capital LLC Sells 10,902 Shares of Exact Sciences Corporation $EXAS - MarketBeat
FMR LLC Reduces Stake in Exact Sciences Corp by 30.88% - GuruFocus
Graham Capital Management L.P. Buys New Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs - Nasdaq
Exact Sciences price target raised to $85 from $65 at Craig-Hallum - Yahoo Finance
Vident Advisory LLC Sells 7,937 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences (NASDAQ:EXAS) Cut to Hold at Zacks Research - MarketBeat
Exact Sciences (EXAS) Is Up 11.2% After Launching Cancerguard Multi-Cancer Blood Test With Quest Diagnostics - simplywall.st
Exact Sciences launches blood test that can detect cancers earlier - Wisconsin State Journal
EFG Asset Management North America Corp. Decreases Stock Position in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences launches Cancerguard blood test for early cancer detection By Investing.com - Investing.com Australia
Exact Sciences Corporation $EXAS Stock Position Decreased by Northwestern Mutual Wealth Management Co. - MarketBeat
Exact Sciences Launches Cancerguard™, Multi-Cancer Early Detection Blood Test - Nasdaq
Exact Sciences’ Cancerguard MCED test launches for $689 - BioWorld MedTech
Should You Continue to Hold EXAS Stock in Your Portfolio? - Nasdaq
Exact Sciences launches Cancerguard blood test for early cancer detection - Investing.com
Exact Sciences launches Cancerguard multi-cancer blood test at $689 - StreetInsider
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test - Quantisnow
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):